In a late-stage trial, treatment with Ipsen and Genfit’s elafibranor led to high rates of biochemical response and the normalization of alkaline phosphatase levels compared with placebo.
https://www.pharmalive.com/wp-content/uploads/2023/09/liver-damage.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-11-14 08:59:562023-11-14 09:27:52Ipsen, Genfit build case for rare liver disease drug with Phase III data
